Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Alumis Inc. Common StockNASDAQ: ALMS
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables falls 50.9% from a year ago
Net receivables stood at $3.86M at the end of Q2 FY2026, down 50.9% from a year earlier and up 41.4% from the prior quarter. Over 3 fiscal years it compounded at +60.9% a year.
Context
- Net receivables amounted to 0.7% of total assets at the end of Q2 FY2026, down 0.6 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -50.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 2.08M USD
- Year-over-year change
- +15.0%
- 3-year CAGR
- +60.9%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.08M | +15.0% |
| FY2024 | 2024-12-31 | 1.81M | +151.0% |
| FY2023 | 2023-12-31 | 722K | +44.4% |
| FY2022 | 2022-12-31 | 500K | — |
Net Receivables vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -50.9% is the 7th highest of 8, against a peer median of +15.3%.
- Net receivables amounts to 0.7% of total assets for ALMS, versus a peer median of 2.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $49.95M USD | +20.2% | +8.7% | 9.9% | |
| Mar 2026 | $25.75M USD | +44.0% | +187.9% | 7.8% | |
| Mar 2026 | $4.81M USD | +1825.6% | +125.7% | 2.4% | |
| Dec 2025 | $4.26M USD | +15.3% | -10.1% | 37.0% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $3.86M USD | -50.9% | +60.9% | 0.7% |
| Mar 2026 | €1.65M EUR | -2.4% | -0.1% | 3.4% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $600K USD | -42.0% | +13.5% | 0.6% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €0 EUR | — | — | 0.0% |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +15.3% | +11.1% | 2.4% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.